A synthetic analog of alpha-melanocyte-stimulating hormone that acts broadly across the melanocortin receptor family; PT-141, which we already offer, is its more selective metabolite.
Coming soon
You are on the list. We will email you if Melanotan II becomes available — and nothing else. Joining is not a medical request, and no prescription has been issued.
That did not go through. Check the address and try again.
Melanotan II is not available through Promise, and may never be; the waitlist gauges interest, and only a licensed provider could ever decide it fits.
How it works once Melanotan II is available
Every treatment gets its own online clinical questionnaire — your history, medications, and goals.
A clinician reads your history and takes the time to get it right before anything is prescribed.
Compounded for your prescription and shipped cold-chain, with care-team check-ins after.
Melanotan II is easy to find online and hard to trust there. Promise works the way medicine is supposed to work — a clinician decides, a licensed pharmacy fills, and someone stays accountable to you.
Prescribed for you specifically, after a real look at your health history — never pulled off a shelf.
Your prescription is compounded for you by a licensed U.S. pharmacy — not a mystery vial from an unregulated website.
Temperature-safe shipping, follow-up check-ins, and a care team that answers — before and after your medication arrives.
Melanotan II is an analog of alpha-melanocyte-stimulating hormone and activates several receptors in the melanocortin family rather than one. That breadth is the whole story of the compound.
Melanocortin signaling touches pigmented tissue. Changes to moles or other pigmented lesions are a reason a provider would evaluate carefully, and a reason skin history matters here.
Melanotan II cannot be prescribed through Promise today.
Melanotan II is not available through Promise. There is no intake questionnaire for it, no price, and no date — and of everything on our waitlist, this is the compound least certain to arrive. Whether it can be offered responsibly is a clinical question our provider network has not answered.
That is the honest frame for this page. What follows explains the compound, its relationship to a treatment we do offer, and why it in particular is one no one should be making decisions about on their own.
Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone, a signaling peptide the body produces itself. It acts as an agonist at melanocortin receptors — and the important word is plural. The melanocortin family has several members, they sit in different tissues, and they are involved in unrelated processes. Melanotan II engages across them rather than picking one.
That breadth is the entire character of the compound. It is why research interest has covered both pigmentation pathways and central pathways related to sexual function, and it is also why it is harder to reason about than a targeted molecule. A drug with one address is easier to predict than a drug with several.
The connection is more than a family resemblance. PT-141 — bremelanotide — is a metabolite of Melanotan II. The body produces it as Melanotan II is broken down, and it acts on the same receptor family.
The difference is selectivity, and it runs in PT-141's favor. PT-141 is the narrower, better characterized of the two, with a genuine Western clinical development record behind it, and it is already prescribed here in mood and libido after a provider review. Melanotan II is the broader parent, studied far less rigorously.
So the honest observation is this: for the pathway most people are asking about, the more selective, better understood molecule is the one that already exists on this site. Melanotan II is not an upgrade to it. If anything, the research history reads the other way around.
Melanocortin signaling reaches pigmented tissue. That is straightforward pharmacology, and it is the reason a person's skin history is directly relevant here. Any change in a mole or other pigmented lesion is something a clinician examines rather than monitors from a distance, and a provider evaluating a request for a melanocortin agonist would want that history up front and would want a plan for watching it afterward.
There is more on the list. Nausea and flushing are commonly reported with this class. There are cardiovascular questions that deserve a full history rather than a checkbox. And material sold outside a pharmacy channel has drawn warnings from health authorities in several countries, which is a purity and identity problem on top of a pharmacological one.
None of that makes the compound unmentionable. It makes it a compound where the clinician gate is the substance of the offering rather than a formality attached to it.
Melanotan II has been studied in humans, but the record is thin by the standards that matter — small studies, older work, and a development history that stopped short of approval anywhere. Much of what circulates about it online is not research at all; it is self-experimentation reported by people with no way to verify what they injected.
This page therefore makes no claim about appearance, no claim about pigmentation as a benefit, and no claim about sexual performance. We are not offering Melanotan II for cosmetic use, and we would not. Describing the receptors a molecule binds is not the same as promising what it will do for a person, and we are not going to blur the two.
Melanotan II sits on a waitlist and nowhere else. If it were ever offered, it would come with an intake questionnaire written specifically for it, a licensed provider reading that intake against your full history, and a prescription only where the risks are genuinely worth it. Not everyone qualifies; on this compound, most would not.
Until then the useful answer is the one already on the site: PT-141 is available, better studied, and prescribed after the same review. That is where a serious conversation about this receptor family should start.
Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone, one of the body's own signaling peptides. It acts as an agonist at melanocortin receptors, and unlike more targeted molecules it engages several of them rather than one. Those receptors sit in different tissues and are involved in different processes, including pigmentation and central pathways related to sexual function. Melanotan II is not available through Promise.
Directly. PT-141, also called bremelanotide, is a metabolite of Melanotan II — the body produces it as Melanotan II is broken down — and it acts on the same receptor family. The difference that matters is selectivity. PT-141 is the more selective and far better characterized of the two, with a real Western clinical record behind it. Melanotan II is the broader, less studied parent compound. If what interests you is the pathway PT-141 works on, PT-141 is the one that already exists here as a prescribed treatment.
No. Melanotan II is not FDA-approved. It would be prepared as a compounded medication, and compounded medications are not reviewed by the FDA for safety, effectiveness, or quality. It has never completed a U.S. approval process, and unregulated material sold outside a pharmacy channel has been the subject of health-authority warnings in several countries.
We are not taking requests for it and there is no committed date. It may not launch at all — a broad melanocortin agonist raises more clinical questions than most of our catalog, and whether it can be offered responsibly is a decision for our provider network, not a matter of demand. The waitlist tells us who is interested; it does not commit us to building the page out.
Because a molecule that activates several receptors at once has effects in several tissues at once, and a person cannot assess that for themselves. Melanocortin signaling reaches pigmented tissue, so any change in a mole or other pigmented lesion is something a clinician would want to examine rather than watch. Reported effects also include nausea and flushing, and there are cardiovascular questions worth a proper history. A licensed provider reviews every request and prescribes only when treatment is appropriate.
Other Mood & Libido options a provider may consider.
Mood & Libido
A melanocortin receptor agonist, also called bremelanotide, studied for central nervous system pathways involved in sexual desire rather than peripheral blood flow.
Requires an online medical evaluation. Prescribed only when a licensed provider determines it's appropriate.
Mood & Libido
A neuropeptide studied upstream of the reproductive hormone axis, where it signals the hypothalamus to release GnRH and set the rest of the cascade in motion.
Requires an online medical evaluation. Prescribed only when a licensed provider determines it's appropriate.